Hyderabad: Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and developer of vaccines for infectious diseases, on Tuesday announced that iNCOVACC® (BBV154), the world's first Intranasal vaccine, is scheduled to be introduced in the country as a booster dose shortly.
Earlier this month, Bharat Biotech received approval from the Central Drugs Standard Control Organization (CDSCO) for the use of heterologous booster doses of iNCOVACC.
iNCOVACC® is now available on CoWin, and priced at INR 800 for private markets and priced at INR 325 for supplies to Government of India and State Governments.
iNCOVACC® is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion-stabilized SARS-CoV-2 spike protein, Hyderabad-based vacciner maker said in a release here.
This vaccine candidate was evaluated in phases I, II and III clinical trials with successful results. iNCOVACC® has been specifically formulated to allow intranasal delivery through nasal drops.
The nasal delivery system has been designed and developed to be cost-effective in low and middle-income countries.
Dr. Krishna Ella, Executive Chairman said; we have developed COVAXIN and iNCOVACC®, two COVID vaccines from two different platforms, with two different delivery systems.
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics.
We thank the Ministry of Health, CDSCO, Department of Biotechnology, Government of India, Technology Development Board, and Washington University, St Louis, for their support and guidance.”
As a needleless vaccination, Bharat Biotech's iNCOVACC will be India's first such booster dose and it will now have more options when it comes to third doses or precautionary doses.
iNCOVACC’s manufacturing platform has the double benefit of enabling faster development of variant-specific vaccines and easy nasal delivery that enables mass immunization to protect from emerging variants of concern.
Clinical trials were conducted to evaluate iNCOVACC as a primary dose schedule, and as heterologous booster dose for subjects who have previously received two doses of the two commonly administered COVID vaccines in India.
iNCOVACC was developed in partnership with Washington University, St. Louis, which had designed and developed the recombinant adenoviral vectored construct and evaluated in preclinical studies for efficacy.
Product development related to preclinical safety evaluation, large-scale manufacturing scale-up, formulation and delivery device development, including human clinical trials were conducted by Bharat Biotech.
Product development and clinical trials were funded in part by the Government of India, through the Department of Biotechnology’s, COVID Suraksha Program.
Despite the lack of demand for COVID vaccines, Bharat Biotech continued product development in intranasal vaccines, to be well-prepared with platform technologies for future infectious diseases.
iNCOVACC has been designed for efficient distribution and easy pain free administration. Bharat Biotech has also initiated development of variant-specific vaccines for COVID in an attempt to be future ready.
iNCOVACC® is stable at 2-8°C for easy storage and distribution. Bharat Biotech has established large manufacturing capabilities at multiple sites across India, including in Gujarat, Karnataka, Maharashtra and Telangana, with operations pan India.
Located in Genome Valley in Hyderabad, a hub for the global biotech industry, BBIL has built world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution. (UNI)